Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Resistant Pseudomos aeruginosa Infections – Overview
Resistant Pseudomos aeruginosa Infections – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Resistant Pseudomos aeruginosa Infections – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Resistant Pseudomos aeruginosa Infections – Companies Involved in Therapeutics Development
Resistant Pseudomos aeruginosa Infections – Drug Profiles
Resistant Pseudomos aeruginosa Infections – Dormant Projects
Resistant Pseudomos aeruginosa Infections – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Resistant Pseudomonas aeruginosa Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Resistant Pseudomonas aeruginosa Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Resistant Pseudomonas aeruginosa Infections – Pipeline by Armata Pharmaceuticals Inc, 2022
Resistant Pseudomonas aeruginosa Infections – Pipeline by Biolytics Pharma, 2022
Resistant Pseudomonas aeruginosa Infections – Pipeline by BiomX Inc, 2022
Resistant Pseudomonas aeruginosa Infections – Pipeline by Boston Pharmaceuticals Inc, 2022
Resistant Pseudomonas aeruginosa Infections – Pipeline by Gnubiotics Sciences SA, 2022
Resistant Pseudomonas aeruginosa Infections – Pipeline by Infex Therapeutics Ltd, 2022
Resistant Pseudomonas aeruginosa Infections – Pipeline by Linnaeus Bioscience Inc, 2022
Resistant Pseudomonas aeruginosa Infections – Pipeline by MetalloBio Ltd, 2022
Resistant Pseudomonas aeruginosa Infections – Pipeline by Shionogi & Co Ltd, 2022
Resistant Pseudomonas aeruginosa Infections – Pipeline by VenatoRx Pharmaceuticals Inc, 2022
Resistant Pseudomonas aeruginosa Infections – Dormant Projects, 2022
Resistant Pseudomonas aeruginosa Infections – Dormant Projects, 2022 (Contd..1)